Photo used for illustrative purpose.
Gulf Today Report
The World Health Organization (WHO) has listed two versions of the AstraZeneca/Oxford Covid-19 vaccine for emergency use including the one produced by the Serum Institute of India, reports IANS.
The other version is produced by AstraZeneca-SKBio (Republic of Korea), the WHO said on Monday.
The approval of these vaccines means giving the green light for them to be rolled out globally through COVAX.
It also allows countries to expedite their own regulatory approval to import and administer Covid-19 vaccines.
"Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk, contributing to the COVAX Facility's goal of equitable vaccine distribution," Mariangela Simao, WHO Assistant-Director General for Access to Medicines and Health Products, said in a statement.
'But we must keep up the pressure to meet the needs of priority populations everywhere and facilitate global access. To do that, we need two things -- a scale-up of manufacturing capacity, and developers' early submission of their vaccines for WHO review."
In the case of the two AstraZeneca/Oxford vaccines, WHO assessed the quality, safety and efficacy data, risk management plans and programmatic suitability, such as cold chain requirements. The process took under four weeks.
The AstraZeneca/Oxford product is a viral vectored vaccine called ChAdOx1-S (recombinant).
It is being produced at several manufacturing sites, as well as in the Republic of Korea and India.
ChAdOx1-S has been found to have 63.09 per cent efficacy and is suitable for low- and middle-income countries due to easy storage requirements.
The WHO earlier approved the Pfizer-BioNTech Covid-19 vaccine for emergency use.
Across Britain, some people who have been counting down the days to their first COVID-19 jab are suddenly suffering doubts – among them my wife, Rachel, who was due to have it on Tuesday. The suspension of the roll out of the Oxford/AstraZeneca
The UN health agency also said that after the injection of more than 260 million coronavirus vaccine doses so far around the world, no deaths had yet been attributed to a COVID-19 jab.
This is with reference to the COVID-19 vaccination drive in India. Covishield has been developed by Oxford University and AstraZeneca. Covaxin has been produced by Bharat Biotech. The Phase 3 trials of Covaxin are not yet complete. Hence some doctors and health
The new training hub comes after the UN agency set up a technology transfer hub in Cape Town, South Africa, last year to give companies from poor and middle-income countries the know-how to produce COVID-19 vaccines based on mRNA technology.
Presenting the plans, US Ambassador to Germany Amy Gutmann said that while the exercise was purely defensive in nature, it was intended to send a message to countries including Russia.
The Central Bank of the UAE (CBUAE) has cancelled the registrations of Seagull Insurance Services Co. and Al Shorafa Insurance Services from the insurance broker register, in accordance with the applicable insurance brokers’ regulation.
The top US diplomat arrived in Saudi Arabia late on Tuesday for a much anticipated visit, his second since becoming America's top diplomat.